Prevalence of Failure of First-Line Anti-Retroviral Therapy in HIV Patients : A Retrospective Cross-Sectional Study of Six Districts of Andhra Pradesh Over One Decade
暂无分享,去创建一个
[1] S. Sundar,et al. Predictive markers of failure of first line anti retroviral treatment in HIV patients in India. , 2013 .
[2] R. Pandey,et al. Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India , 2012, AIDS research and treatment.
[3] R. Paranjape,et al. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. , 2011, AIDS research and human retroviruses.
[4] L. Pinoges,et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda , 2009, BMC infectious diseases.
[5] L. Jeyaseelan,et al. Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience , 2007, AIDS.
[6] A. Vibhagool,et al. Experience with the use of a first‐line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database , 2007, HIV medicine.
[7] T. Flanigan,et al. Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India , 2006, Journal of acquired immune deficiency syndromes.
[8] T. Quinn,et al. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. , 2006, The Lancet. Infectious diseases.
[9] E. Nicastri,et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy , 2005, AIDS.
[10] E. Naik,et al. Effectiveness of Generic Fixed-Dose Combinations of Highly Active Antiretroviral Therapy for Treatment of HIV Infection in India , 2004, Journal of acquired immune deficiency syndromes.
[11] A. Mocroft,et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. , 2004, The Journal of infectious diseases.
[12] T. Flanigan,et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India , 2003, AIDS.
[13] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[14] Jeffrey N. Martin,et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia , 2002, AIDS.
[15] Julio S. G. Montaner,et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.
[16] W. Bilker,et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load , 2001, AIDS.
[17] K. D. de Cock,et al. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. , 1999, AIDS.
[18] J. Rabkin,et al. Adherence: a necessity for successful HIV combination therapy. , 1999, AIDS.
[19] B Clotet,et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.
[20] W. O'brien,et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. , 1988, Science.